| 57.69 0.15 (0.26%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.85 | 1-year : | 81.59 |
| Resists | First : | 59.81 | Second : | 69.85 |
| Pivot price | 52.87 |
|||
| Supports | First : | 45.66 |
Second : | 36.91 |
| MAs | MA(5) : | 57.53 |
MA(20) : | 49.76 |
| MA(100) : | 49.29 |
MA(250) : | 34.69 |
|
| MACD | MACD : | 4 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 88.4  |
D(3) : | 90.6 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 67.2 | Low : | 12.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRAX ] has closed below upper band by 23.8%. Bollinger Bands are 40.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 59.55 - 59.77 | 59.77 - 59.95 |
| Low: | 56.88 - 57.16 | 57.16 - 57.38 |
| Close: | 57.28 - 57.7 | 57.7 - 58.04 |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Wed, 24 Jul 2024
6,750 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by BNP Paribas Financial Markets - Defense World
Tue, 23 Jul 2024
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Acadian Asset Management LLC - MarketBeat
Tue, 23 Jul 2024
Acadian Asset Management LLC Sells 15,795 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Thu, 18 Jul 2024
Piper Sandler bullish on Praxis Precision Medicines stock citing focal epilepsy potential - Investing.com
Tue, 16 Jul 2024
Analysts Set Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Price Target at $137.38 - American Banking and Market News
Mon, 24 Jun 2024
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.211e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 702 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2973e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 718.3 % |
| Return on Equity (ttm) | -46.7 % |
| Qtrly Rev. Growth | 2.19e+006 % |
| Gross Profit (p.s.) | -13.37 |
| Sales Per Share | -30.89 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.3 |
| Price to Book value | 0 |
| Price to Sales | -1.87 |
| Price to Cash Flow | 9.19 |
| Dividend | 0 |
| Forward Dividend | 1.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|